Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice

Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in cancer biology and infectious disease suggests that tar...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 4; p. e61646
Main Authors Kourtis, Iraklis C, Hirosue, Sachiko, de Titta, Alexandre, Kontos, Stephan, Stegmann, Toon, Hubbell, Jeffrey A, Swartz, Melody A
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 23.04.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Nanoparticles have been extensively developed for therapeutic and diagnostic applications. While the focus of nanoparticle trafficking in vivo has traditionally been on drug delivery and organ-level biodistribution and clearance, recent work in cancer biology and infectious disease suggests that targeting different cells within a given organ can substantially affect the quality of the immunological response. Here, we examine the cell-level biodistribution kinetics after administering ultrasmall Pluronic-stabilized poly(propylene sulfide) nanoparticles in the mouse. These nanoparticles depend on lymphatic drainage to reach the lymph nodes and blood, and then enter the spleen rather than the liver, where they interact with monocytes, macrophages and myeloid dendritic cells. They were more readily taken up into lymphatics after intradermal (i.d.) compared to intramuscular administration, leading to ∼50% increased bioavailability in blood. When administered i.d., their distribution favored antigen-presenting cells, with especially strong targeting to myeloid cells. In tumor-bearing mice, the monocytic and the polymorphonuclear myeloid-derived suppressor cell compartments were efficiently and preferentially targeted, rendering this nanoparticulate formulation potentially useful for reversing the highly suppressive activity of these cells in the tumor stroma.
Bibliography:Conceived and designed the experiments: ICK SH SK. Performed the experiments: ICK SH AdT SK. Analyzed the data: ICK SH. Contributed reagents/materials/analysis tools: ICK SH AdT TS. Wrote the paper: ICK SH MAS JAH.
Competing Interests: This study was partly funded by Carigest SA. Toon Stegmann is employed by Mymetics BV. The EPFL has filed for patent protection on the nano particles described. There are no further patents products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0061646